Mumbai Police Crime Branch team brings Bhavesh Bhinde (in black cloth), an accused in the Ghatkopar hoarding collapse case, from Udaipur, at the Mumbai Airport.  Photo | PTI
India

Ghatkopar hoarding collapse: Prime accused Bhavesh Bhinde gets bail

Bhinde has been booked for 'culpable homicide not amounting to murder.'

PTI

MUMBAI: A court here on Saturday granted bail to advertising firm director Bhavesh Bhinde, a prime accused in the Ghatkopar hoarding collapse case.

Bhinde's bail plea was allowed by additional sessions Judge V M Pathade.

The detailed order was not available yet.

Bhinde, through his lawyer Sana Khan, had contended that the "unfortunate incident " that claimed 17 lives in May this year was an "act of God", and he was "implicated for political vendetta."

The hoarding installed in suburban Ghatkopar area collapsed due to "unexpected, unusual wind speed" and no fault can be attributed to the applicant (whose firm had installed it), advocate Khan argued.

It was also submitted that Bhinde was not the director of the firm at the time of the installation of the gigantic hoarding.

Bhinde has been booked for `culpable homicide not amounting to murder.'

The prosecution opposed bail to him, saying there was enough evidence to show that Bhinde was actively involved in the case.

As many as 17 people, including a former general manager of the Mumbai airport's Air Traffic Control and his wife, died after the billboard crashed onto a petrol pump on May 13 during sudden dusty winds and unseasonal rains.

It was alleged that the hoarding had been put up illegally on railway land.

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’